Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-21

Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 trial of baricitinib in systemic lupus erythematosus completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2018-11-21